Blistering disease associated with diffuse large B‐cell lymphoma but without autoantibodies

Yamate, Tomoko; Shono, Toshiyuki; Shimada, Hideaki; Ishikawa, Kazushi; Hatano, Yutaka; Kohno, Kazuhiro; Yamamoto, Takenobu; Fujimoto, Wataru; Yamaguchi, Mari; Aoyama, Yumi; Ishii, Norito; Hashimoto, Takashi; Fujiwara, Sakuhei

doi:10.1111/1346-8138.13198

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the occurrence of blisters in B-cell lymphomas is extremely rare and has only been reported once in the literature [2]. An association of blistering diseases with DLBCL has been described with a paraneoplastic pemphigus-like eruption with negative autoantibodies [4]. Eosinophilic dermatosis of myeloproliferative disease presenting with edematous nodules with central vesicular eruption was reported once in a patient with stage IV systemic DLBCL [5].…”

Section: Case Discussionmentioning

confidence: 99%

Secondary cutaneous diffuse large B-cell lymphoma presenting with focal vesicular lesions

Alsukait¹,

Taher²,

AlJasser³

2022

DOJ

View full text Add to dashboard Cite

Section: Case Discussionmentioning

confidence: 99%

Secondary cutaneous diffuse large B-cell lymphoma presenting with focal vesicular lesions

Alsukait¹,

Taher²,

AlJasser³

2022

DOJ

View full text Add to dashboard Cite

“…As a cancer of immune cells, DLBCL perturbs immune networks, resulting in qualitative and quantitative dysfunction via a reduction in normal B cells and loss of normal communication between B cells and other immune cells. [18][19][20] In addition, treatments for DLBCL, including rituximab, 21,22 corticosteroids, 23 newer agents such as lenalidomide, 24 and radiotherapy and chemotherapy, 25 all have profound effects on the immune system. Whether these result in lasting changes to immune function, especially changes that might persist in the absence of active disease and treatment, is unknown.…”

Section: Introductionmentioning

confidence: 99%

Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma

Shree

Glaser

et al. 2020

JCO

View full text Add to dashboard Cite

PURPOSE Therapeutic advances for diffuse large B-cell lymphoma (DLBCL) have led to an increasing number of survivors. Both DLBCL and its treatments perturb the immune system, yet little is known about immune health during extended survivorship. METHODS In this retrospective cohort study, we compared 21,690 survivors of DLBCL from the California Cancer Registry (CCR) to survivors of breast, prostate, head and neck, and melanoma cancers. We linked their CCR records to a statewide database documenting hospital, emergency room, and ambulatory surgery visits and investigated the incidence of autoimmune conditions, immune deficiencies, and infections 1-10 years after cancer diagnosis. RESULTS We found elevated incidence rate ratios (IRRs) for many immune-related conditions in survivors of DLBCL compared with other cancer survivors, including significantly and consistently elevated IRRs for viral and fungal pneumonias (up to 10.8-fold), meningitis (up to 5.3-fold), as well as humoral deficiency (up to 17.6-fold) and autoimmune cytopenias (up to 12-fold). IRRs for most conditions remained high even in the late survivorship period (5-10 years after cancer diagnosis). The elevated risks could not be explained by exposure to chemotherapy, stem-cell transplantation, or rituximab, except for IRRs for humoral deficiency, which were consistently higher after the incorporation of rituximab into DLBCL treatments. CONCLUSION To our knowledge, this is the largest cohort study with extended follow-up to demonstrate impaired immune health in survivors of DLBCL. The observed persistent, elevated risks for autoimmune diseases, immune deficiencies, and infectious conditions may reflect persistent immune dysregulation caused by lymphoma or treatment and may lead to excess morbidity and mortality during survivorship. Improved understanding of these risks could meaningfully improve long-term care of patients with DLBCL.

show abstract

Blistering disease associated with diffuse large B‐cell lymphoma but without autoantibodies

Cited by 2 publications

References 7 publications

Secondary cutaneous diffuse large B-cell lymphoma presenting with focal vesicular lesions

Secondary cutaneous diffuse large B-cell lymphoma presenting with focal vesicular lesions

Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma

Contact Info

Product

Resources

About